Apoquel Chewable Tablet
Apoquel is an FDA-approved preparation containing Apoquel, for veterinary use. Available by prescription.
Veterinarians most commonly consider Apoquel® for the management of clinical signs in dogs experiencing acute or chronic dermatological health challenges. It is frequently a point of discussion when a patient's scratching, licking or chewing has become a significant clinical concern, or when other interventions have not provided sufficient physiological support. By modulating specific biochemical pathways involved in the itch-scratch cycle, your veterinarian can manage the comfort of the patient while diagnostic investigations into the underlying allergy continue.
At a pharmacological level, oclacitinib acts as a selective inhibitor of Janus kinase enzymes, with a particular affinity for JAK1 and JAK3. These enzymes are essential components of the signaling pathways for various pro-inflammatory and pruritogenic (itch-inducing) cytokines, including interleukin-31 (IL-31). By blocking these intracellular signals, the medication may help address the transmission of the "itch" signal from the skin to the nervous system and modulates the inflammatory response. Unlike traditional medications such as corticosteroids, oclacitinib possesses a more targeted mechanism that minimizes influence on other physiological systems. Your veterinarian will determine the clinical appropriateness of Apoquel® based on your pet’s health history and the results of a physical examination.
The actions described here reflect the product's FDA-approved labeling; your veterinarian determines the appropriate use for your animal.
Prescription only. Use only under the direction of a licensed veterinarian. This information is not a substitute for veterinary diagnosis, prescribing or monitoring.
Commonly observed effects following the administration of Apoquel® include gastrointestinal changes such as vomiting or loose stools, which are often transient. Some owners may note localized shifts in energy levels or a decrease in appetite. Because this medication influences the immune signaling pathways, your veterinarian will monitor for any signs of secondary infections or unusual skin growths during the protocol. Owners should watch for persistent behavioral shifts or physical changes and contact their veterinarian promptly if these occur.
This medication is typically used with extra caution or avoided in dogs under 12 months of age, those with serious systemic infections or patients with a history of certain cancers. It is also carefully evaluated in breeding, pregnant or lactating dogs, as specific safety data for these categories are limited. Before starting a protocol, ensure your veterinarian has a complete history of all other prescriptions and supplements your pet is receiving. Your veterinarian is the right person to provide guidance on the necessary duration of use and the most commonly considered monitoring schedule to ensure the management approach remains suitable for your pet's individual health status.
Yes. Apoquel® is a prescription medication and can only be dispensed by a licensed pharmacy upon receipt of a valid authorization from a licensed veterinarian. Mixlab verifies all authorizations before any medication is shipped to your home.
Yes. While Apoquel® is available as a commercial tablet, Mixlab can compound the active ingredient, oclacitinib, into specialized strengths or alternative flavored dosage forms—such as flavored oral liquids or chewable may be considered in cases of—if your veterinarian determines a customized preparation better suits your pet's needs. The decision between a commercial and compounded product rests with the prescribing veterinarian.
Apoquel® is not a corticosteroid or an antihistamine; it belongs to a class of medications called Janus kinase (JAK) inhibitors. Veterinarians often discuss this distinction because oclacitinib targets the itch signaling pathway more specifically than steroids, which can have broader physiological effects on the body.
Veterinarians generally discuss Apoquel® for its rapid onset, often observing a decrease in scratching behaviors within the first 24 hours of administration. While the medication acts quickly to manage the physiological itch response, long-term management protocols are designed by your veterinarian based on the patient's specific allergic triggers.
